Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Darzalex Faspro (daratumumab and hyaluronidase-fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
FDA approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation in newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplant (ASCT), supported by Phase 3 PERSEUS study data showing significant improvement in progression-free survival (PFS) and deeper responses with D-VRd compared to VRd.
Trends in biosimilars: Regulatory approvals in 2024
The biosimilars market is expanding, with the global market projected to hit $43.8 billion by 2024 and exceed $100 billion in a decade. Recent FDA and EMA approvals include biosimilars for Johnson & Johnson’s Stelara and Bayer’s Eylea, following patent expirations. Notable approvals include Pyzchiva, Ahzantive, Yesafily, Opuviz, Hercessi, Selarsdi, Wyost, Jubbonti, Simlandi, and Uzpruvo, targeting various conditions and expected to launch by 2025.
Global Tenosynovial Giant Cell Tumor Treatment Market
The Global Tenosynovial Giant Cell Tumor Treatment Market Report by WMR offers a detailed analysis of market growth, trends, and key players. It combines qualitative and quantitative data, covering market size, share, and dynamics. Major companies include Novartis, Roche, and Pfizer. The report segments the market by types, applications, and regions, providing insights into opportunities and future growth.
New FDA and EMA Oncology Drug Approvals in Q2 2024 Largely Focused on Biologics and Specific Molecular Targets
In Q2 2024, FDA and EMA approved 26 new/expanded indications and 9 new oncology agents, targeting 19 solid tumors and 5 hematologic malignancies. Highlights include 6 NSCLC treatments, 4 tumor-agnostic approvals, and 3 biologics for follicular lymphoma. Key approvals: alectinib, durvalumab, epcoritamab. Safety updates included hepatotoxicity risks and CAR T-cell therapy warnings.
Drug discovery hotspots: What is the secret to Switzerland's success
Switzerland excels in life sciences due to its strong regional hubs like Basel, Zurich, and Geneva/Lausanne, fostering innovation through bioparks and collaboration between academia and industry. This ecosystem supports start-ups and attracts global talent, maintaining Switzerland's leadership in drug discovery and biotech advancements.
Cilta-Cel Generates OS Benefit in R/R Myeloma After 1 Prior Therapy
Ciltacabtagene autoleucel (cilta-cel) showed significant overall survival benefits in relapsed/refractory multiple myeloma patients, per CARTITUDE-4 study. FDA expanded cilta-cel's indication, making it the first cell therapy to improve survival early in treatment. Safety aligns with its label, despite risks like cytokine release syndrome.
Dementia Global Clinical Trials Review 2024: Comparative Scenario of Completed and Uncompleted (Terminated, Suspended, Withdrawn) Trials
The "Dementia - Global Clinical Trials Review, 2024" report offers an overview of dementia clinical trials globally, including data by region, country, phase, status, and sponsor type. It highlights enrollment trends, key companies, and drugs in ongoing trials, aiding strategic decision-making and identifying business opportunities.
Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara
Samsung Bioepis's Pyzchiva, a biosimilar to J&J's Stelara, approved by FDA for treating severe plaque psoriasis, psoriatic arthritis, Crohn’s, and ulcerative colitis. Set for U.S. commercialization by Sandoz, with competition from Alvotech, Teva, and Amgen biosimilars starting February 2025. J&J's Stelara sales hit $2.4B in Q1 2024, below the $2.6B estimate.
Johnson & Johnson submits BLA to FDA for lung cancer drug
Johnson & Johnson seeks FDA approval for SC amivantamab in NSCLC treatment, showing comparable efficacy to IV form in Phase III trials. The SC version offers a quicker administration, aiming to improve patient and healthcare provider experience.
EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments
At EHA 2024, key studies on MM treatments were presented, including DREAMM-8, LINKER-MM1, and GMMG-HD7. Blenrep showed promising results in RRMM, with a 77% ORR. Linvoseltamab demonstrated efficacy in RRMM, with a 71% ORR. Sarclisa improved treatment responses in newly diagnosed MM, showing higher MRD negativity rates.
Related Clinical Trials:
© Copyright 2025. All Rights Reserved by MedPath